Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesHematology/OncologyCigna Factor VIII Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0618

    Factor VIII Products

    Customize your policy alerts

    Sign up for Cigna Policy IP0618 alerts

    Get alerted when Policy IP0618 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for specified recombinant and plasma-derived Factor VIII products administered under Cigna health benefit plans for patients with hemophilia A or, for selected products, von Willebrand disease.

    Policy Summary
    PayerCigna
    PolicyFactor VIII Products
    Policy CodePolicy IP0618
    Change TypeModified
    Effective DateSep 15, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests only when the applicable coverage criteria and dosing requirements are met.
    SourceLink
    POLICY UPDATE CHANGES

    Dosing information was added for all products.

    Preferred-product criteria and exceptions were updated for Alphanate, Humate-P, and Wilate.

    Stimate nasal spray was removed from the policy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    17Products subject to recommended prior authorization
    1 yearCovered approval duration
    4Extended half-life products
    3Products with von Willebrand disease criteria
    15Medically necessary HCPCS codes

    Medical Necessity and Coverage Criteria

    Recombinant Factor VIII products for hemophilia A

    Covered as medically necessary when all applicable indication, specialist, and dosing requirements are met.

    All applicable requirements

    • Requested products: The requested agent is Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, or Xyntha for hemophilia A.
    • Hemophilia A: The requested agent is for hemophilia A.

      Approval is for 1 year.

    • Specialist involvement: The agent is prescribed by or in consultation with a hemophilia specialist.

    • Permitted dosing regimen

      • Extended half-life routine prophylaxis: Adynovate, Eloctate, Esperoct, or Jivi is requested for routine prophylaxis.Up to 100 IU/kg intravenously no more frequently than twice weekly
      • Extended half-life bleeding treatment: Adynovate, Eloctate, Esperoct, or Jivi is requested for on-demand treatment and control of bleeding episodes.Up to 65 IU/kg intravenously no more frequently than once every 8 hours for up to 10 days per episode
      • Extended half-life perioperative management: Adynovate, Eloctate, Esperoct, or Jivi is requested for perioperative management.Up to 65 IU/kg intravenously no more frequently than once every 6 hours for up to 10 days per procedure
      • Standard half-life recombinant routine prophylaxis:

    Hemofil M and Koate for hemophilia A

    Covered as medically necessary when all applicable indication, specialist, and dosing requirements are met.

    All applicable requirements

    • Requested products: The requested agent is Hemofil M or Koate for hemophilia A.

      Approval is for 1 year if prescribed by or in consultation with a hemophilia specialist.

    • Hemophilia A: The requested agent is for hemophilia A.
    • Specialist involvement: The agent is prescribed by or in consultation with a hemophilia specialist.

    • Permitted dosing regimen

    Alphanate, Humate-P, and Wilate

    Covered as medically necessary when ONE of the following indications is met, with the applicable specialist and dosing requirements.

    All applicable requirements

    • Requested products: The requested agent is Alphanate, Humate-P, or Wilate.
    • Specialist involvement: The agent is prescribed by or in consultation with a hemophilia specialist.

      Approval is for 1 year.

    • ONE of the following indications

      • Hemophilia A

        • Permitted dosing regimen

          • Routine prophylaxis is requested.

    Von Willebrand disease preferred product criteria

    For Alphanate, Humate-P, or Wilate requests for von Willebrand disease, the applicable plan-specific preferred-product criteria must be met.

    Applicable plan-specific preferred-product pathway

    • Employer plan—Type 1 von Willebrand disease

      • At least one Type 1 qualification

        • The patient has tried desmopressin injection (DDAVP injection).
        • The patient has a severe bleeding phenotype.
        • The patient has very low von Willebrand Factor levels.
    • Type 2 or Type 3 von Willebrand disease: The patient has Type 2 or Type 3 von Willebrand disease.

    Alphanate, Humate-P, and Wilate

    For Individual and Family Plans, Alphanate, Humate-P, and Wilate are covered when the patient meets one of the following qualifying pathways.

    Individual and Family Plan qualifying pathway

    • Type 1 von Willebrand disease—bleeding episodes

      • At least one Type 1 qualification

        • The patient has tried desmopressin injection (DDAVP injection).
        • The patient has a severe bleeding phenotype.
        • The patient has very low von Willebrand Factor levels.
    • Type 2 or Type 3 von Willebrand disease: The patient has Type 2 or Type 3 von Willebrand disease.

    Altuviiio is not involved in this policy.

    The listed Factor VIII products are considered not medically necessary for any use other than the indications and coverage criteria specified in this policy.

    For Type 1 von Willebrand disease, the bleeding-episode criterion does not apply to routine prophylaxis to reduce the frequency of bleeds or to surgery-related use.

    The coverage criteria apply to Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Koate, Alphanate, Humate-P, and Wilate when used for the policy-supported hemophilia A or von Willebrand disease indications and applicable dosing requirements.

    Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Koate, Alphanate, Humate-P, and Wilate are considered not medically necessary for any other use.

    Coding and Dosing Information

    Considered Medically Necessary HCPCS CodesHCPCSCovered
    J7182Injection, Factor VIII, (antihemophilic factor, recombinant), (NovoEight), per IU.
    J7183Injection, von Willebrand factor complex (human), Wilate, 1 IU VWF:RCO.
    J7185Injection, Factor VIII (antihemophilic factor, recombinant) (Xyntha), per IU.
    J7186Injection, antihemophilic Factor VIII/von Willebrand factor complex (human), per Factor VIII IU.
    J7187Injection, von Willebrand factor complex (Humate-P), per IU VWF:RCO.
    J7190Factor VIII (antihemophilic factor, human) per IU; the document also associates J7190 with injection, von Willebrand factor complex (Humate-P), per IU VWF:RCO.
    J7191Factor VIII (antihemophilic factor, human) per IU.
    J7192Factor VIII (antihemophilic factor (porcine)), per IU.
    J7204Injection, Factor VIII, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei, per IU.
    J7205Injection, Factor VIII Fc fusion protein (recombinant), per IU.
    1–10 of 15
    1/2
    Extended half-life product routine prophylaxis
    Maximum doseUp to 100 IU/kg
    RouteIntravenously
    FrequencyNo more frequently than twice weekly
    Extended half-life product on-demand bleeding treatment
    Maximum doseUp to 65 IU/kg
    Route and frequencyIntravenously no more frequently than once every 8 hours
    Episode durationUp to 10 days per episode

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Recommended

    Prior authorization is recommended for medical-benefit coverage of the listed Factor VIII products. Submit requests for the applicable product and indication before treatment.

    • Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Alphanate, Humate-P, Koate, and Wilate
    Documentation Required

    Hemophilia Specialist Required

    The agent must be prescribed by, or provided in consultation with, a physician who specializes in the condition being treated. For covered Hemophilia A and von Willebrand disease indications, approval also requires the applicable hemophilia-specialist involvement.

    • Hemophilia A: prescription by or consultation with a hemophilia specialist is required.
    • Von Willebrand disease: prescription by or consultation with a hemophilia specialist is required, along with the applicable Preferred Product Criteria.

    Clinical Background

    Hemophilia A is an X-linked bleeding disorder caused by Factor VIII deficiency. It may lead to spontaneous or trauma-related bleeding into the joints, bleeding at other body sites, and hemophilic arthropathy. Factor VIII replacement products include extended- and standard-half-life recombinant products as well as plasma-derived products, including products with or without substantial von Willebrand Factor.

    Key Terms

    Hemophilia A
    DefinitionAn X-linked bleeding disorder caused by a deficiency in Factor VIII
    Inheritance patternX-linked; primarily impacts males
    Severity classificationMild, moderate, or severe based on plasma Factor VIII levels or activity
    Factor VIII contextNormal plasma Factor VIII levels range from 50% to 150%; mild disease is 6% to 49%, moderate disease is 1% to 5%, and severe disease is below 1%
    Von Willebrand disease
    DefinitionA group of inherited bleeding disorders related to defects of von Willebrand Factor
    Hemostatic role
    Policy Summary
    PayerCigna
    PolicyFactor VIII Products
    Policy CodePolicy IP0618
    Change TypeModified
    Effective DateSep 15, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests only when the applicable coverage criteria and dosing requirements are met.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Dosing InformationAuthorization, Documentation, and Denial RisksClinical BackgroundKey Terms
    Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, or Xyntha is requested for routine prophylaxis.
    Up to 60 IU/kg intravenously no more frequently than every other day, three or four times weekly
  1. Standard half-life recombinant bleeding treatment: Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, or Xyntha is requested for on-demand treatment and control of bleeding episodes.Up to 50 IU/kg intravenously no more frequently than once every 6 hours for up to 10 days per episode
  2. Standard half-life recombinant perioperative management: Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, or Xyntha is requested for perioperative management.Up to 60 IU/kg intravenously no more frequently than once every 6 hours for up to 10 days per procedure
  3. Immune tolerance therapy: Any listed recombinant product is requested for immune tolerance therapy (immune tolerance induction).Up to 200 IU/kg intravenously no more frequently than once daily
    4. Routine prophylaxis is requested.
    Up to 50 IU/kg intravenously no more frequently than every other day, three or four times weekly
  4. Bleeding treatment or perioperative management: On-demand treatment and control of bleeding episodes or perioperative management is requested.Up to 50 IU/kg intravenously no more frequently than once every 6 hours for up to 10 days per episode or procedure
  5. Immune tolerance therapy (immune tolerance induction) is requested.Up to 200 IU/kg intravenously no more frequently than once daily
    6. Up to 50 IU/kg intravenously no more frequently than every other day, three or four times weekly
  6. Bleeding treatment or perioperative management: On-demand treatment and control of bleeding episodes or perioperative management is requested.Up to 50 IU/kg intravenously no more frequently than once every 6 hours for up to 10 days per episode or procedure
  7. Immune tolerance therapy (immune tolerance induction) is requested.Up to 200 IU/kg intravenously no more frequently than once daily

  8. Von Willebrand disease

    • Permitted dosing regimen

      • Bleeding treatment or perioperative management: On-demand treatment and control of bleeding episodes or perioperative management is requested.Up to 80 IU VWF:RCo/kg intravenously no more frequently than once every 8 hours for up to 10 days per episode or procedure
      • Routine prophylaxis is requested.Up to 100 IU VWF:RCo/kg intravenously no more frequently than once every 2 days
  9. Desmopressin inadequate response or safety concern: The patient has a history of inadequate response to injectable desmopressin or has safety concerns with use of injectable desmopressin.
  10. Employer plan—age under 2 years: The patient is younger than 2 years of age.
  11. Desmopressin inadequate response or safety concern: The patient has a history of inadequate response to injectable desmopressin or has safety concerns with use of desmopressin injection (DDAVP injection).
    12. Extended half-life product perioperative management
    Maximum doseUp to 65 IU/kg
    Route and frequencyIntravenously no more frequently than once every 6 hours
    Procedure durationUp to 10 days per procedure
    Immune tolerance therapy
    Maximum doseUp to 200 IU/kg
    RouteIntravenously
    FrequencyNo more frequently than once daily
    Standard half-life recombinant product routine prophylaxis
    Maximum doseUp to 60 IU/kg
    RouteIntravenously
    FrequencyNo more frequently than every other day (three or four times weekly)
    Standard half-life recombinant product on-demand bleeding treatment
    Maximum doseUp to 50 IU/kg
    Route and frequencyIntravenously no more frequently than once every 6 hours
    Episode durationUp to 10 days per episode
    Standard half-life recombinant product perioperative management
    Maximum doseUp to 60 IU/kg
    Route and frequencyIntravenously no more frequently than once every 6 hours
    Procedure durationUp to 10 days per procedure
    Hemofil M, Koate, Alphanate, Humate-P, or Wilate prophylaxis
    Maximum doseUp to 50 IU/kg
    RouteIntravenously
    FrequencyNo more frequently than every other day (three or four times weekly)
    Hemofil M, Koate, Alphanate, Humate-P, or Wilate bleeding or perioperative treatment
    Maximum doseUp to 50 IU/kg
    Route and frequencyIntravenously no more frequently than once every 6 hours
    DurationUp to 10 days per episode or procedure
    Von Willebrand disease on-demand or perioperative treatment
    Maximum doseUp to 80 IU VWF:RCo/kg
    Route and frequencyIntravenously no more frequently than once every 8 hours
    DurationUp to 10 days per episode or procedure
    Von Willebrand disease routine prophylaxis
    Maximum doseUp to 100 IU VWF:RCo/kg
    RouteIntravenously
    FrequencyNo more frequently than once every 2 days
    Documentation Required

    Clinical Request Documentation

    Clinical requests should identify the requested product, covered diagnosis or indication, prescribing provider, specialist prescription or consultation, and requested regimen. Include the applicable dosing details, including dose per kilogram, frequency, duration, and whether treatment is prophylactic, on-demand, perioperative, or immune-tolerance therapy.

    • Document the requested Factor VIII product and the diagnosis or indication, such as Hemophilia A or von Willebrand disease.
    • Identify the prescribing provider and hemophilia specialist involvement.
    • Document the requested dose, frequency, and duration and show that it matches an established regimen.
    Documentation Required

    Von Willebrand Disease Supporting Documentation

    For Alphanate, Humate-P, and Wilate requests for von Willebrand disease under Employer Plans or Individual and Family Plans, document the applicable plan-specific qualification pathway and supporting clinical facts. Type 1 von Willebrand disease treatment of bleeding episodes does not apply to routine prophylaxis or surgery-related use.

    • Employer Plans and Individual and Family Plans: document that the patient meets at least one applicable pathway.
    • Type 1 von Willebrand disease: document a trial of injectable desmopressin (DDAVP), a severe bleeding phenotype, or very low von Willebrand factor levels.
    • Alternatively, document Type 2 or Type 3 von Willebrand disease; inadequate response to injectable desmopressin or safety concerns with its use; or, where applicable, that the patient is younger than 2 years.
    • For Type 1 disease, specify that the request is for treatment of a bleeding episode rather than routine prophylaxis or surgery-related use.
    Denial Risk

    Unlisted Use Is Not Covered

    Use outside the policy's listed indications is not medically necessary and is not covered under this policy.

    • Applies to Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Koate, Alphanate, Humate-P, and Wilate.
    Denial Risk

    Criteria or Dosing Not Met

    Coverage may be denied when the request does not meet the applicable indication, specialist-prescriber or consultation requirement, or established dosing criteria. Doses outside the established dosing in this policy require case-by-case review by a clinician, such as a Medical Director or Pharmacist.

    • The diagnosis or indication must be one listed in the policy, including Hemophilia A or the applicable von Willebrand disease criteria.
    • The agent must be prescribed by or in consultation with a hemophilia specialist when required.
    • The requested dose, frequency, and duration must fall within an approved regimen unless separately reviewed case by case.
    • Extended approval requires the patient to continue meeting the applicable criteria and dosing.
    Billing Rule

    Billing Codes and Plan Terms Control

    Claims submitted without covered code(s) under the applicable Coverage Policy may be denied as not covered. The customer's applicable benefit-plan document controls if it conflicts with this policy, and benefits are ultimately determined by that plan document absent a controlling mandate.

    • Use the most appropriate billing codes in effect on the submission date.
    • Reimbursement is not allowed for services billed for conditions or diagnoses not covered under the policy.
    • The applicable Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description, or similar plan document supersedes conflicting policy language.
    Denial Risk

    Any Other Use Is Not Medically Necessary

    Hemophilia Factor VIII products used for any use other than the policy's listed indications are considered not medically necessary. Such requests may be denied unless the policy is updated to address new published data.

    • Applies to all listed products, including Factor VIII products and Alphanate, Humate-P, and Wilate.
    Note

    Type 1 von Willebrand Disease Criteria

    For Type 1 von Willebrand disease treatment of bleeding episodes, the patient must meet at least one of the listed alternative pathways. These pathways do not apply to routine prophylaxis or surgery-related use.

    • The patient has tried injectable desmopressin (DDAVP injection).
    • The patient has a severe bleeding phenotype.
    • The patient has very low von Willebrand factor levels.
    • The patient has Type 2 or Type 3 von Willebrand disease.
    • The patient has a history of inadequate response to injectable desmopressin or safety concerns with its use.
    • For Employer Plans, the patient is younger than 2 years of age.
    von Willebrand Factor is needed to achieve hemostasis
    Disease typesTypes 1 and 3 reflect quantitative von Willebrand Factor deficiency; Type 2 reflects qualitative deficiency
    VWF:RCo
    TermVWF:RCo
    MeaningVon Willebrand Factor activity
    Measurement methodMeasured with the Ristocetin cofactor assay